We’ve welcomed HempFusion (TSE:CBD.U) CEO Dr. Jason Mitchell to speak with us at The Dales Report before. We had a great discussion about the company’s regulatory compliance and what things lay in store for the hemp-based CBD company. One of the topics that had come up briefly in that interview was a six-month clinical trial on the effects of CBD on the human body, which HempFusion would be the exclusive brand and sole supplier for. Joining us in this interview is both Dr. Jason Mitchell and Dr. David Harnick, the cardiologist who will be undertaking these clinical trials with HempFusion CBD at Mount Sinai Medical Hospital in NYC.
Here’s some highlights from the interview:
– Research on CBD hard to find – but important to pursue say both Harnick and Mitchell
– Clinical Trial run by Dr Harnick to be a randomized, double-blind placebo-controlled trial
– Conversations improving about the possibilities of medical value in CBD – meaning great things for investors
We are a business news platform that provides the latest and best insight on the stories making headlines around the world. We give Institutional and retail investors an inside edge in the competitive world of investing and profile companies that are making waves in their ever-growing industries.
We are The Dales Report.
Check out our website:
Subscribe to our channel at
Connect with us on our social media handles: